Drug Trial Radar · NCT07659184
IRONCARE: Iron Treatment in Older Patients With Hip Fractures
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
528
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Sep 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- University of AarhusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Region MidtJylland Denmark; Viborg Regional Hospital; Gødstrup Hospital; Aarhus University Hospital; Randers Regional Hospital; Regionshospitalet Horsens
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation. The trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).
Conditions
- Hip Fracture
- Anemia
- Iron
- Placebo - Control
Interventions
Ferric DerisomaltoseDrug
Intravenous Ferric Derisomaltose shortly after surgery and placebo tablets on alternate days for 90 days
Oral Iron (Ferrous sulphate)Drug
Oral iron sulfate on alternate days for 90 days and IV placebo once shortly after surgery
Placebo IVDrug
100 ml Sodium Chloride (NaCl)
Placebo TabletsDrug
Placebo tablets on alternate days for 90 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- FatigueTime frame: Baseline and days 30 and 90 after discharge
- Hemoglobin incrementTime frame: Baseline and days 30 and 90 after discharge
- Safety profileTime frame: Days 15, 30, 45 and 90 after discharge
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Aarhus Univeristy Hospital
Aarhus N, Denmark
Regional Hospital Gødstrup
Herning, Denmark
Regional Hospital Horsens
Horsens, Denmark
Regional Hospital Randers
Randers, Denmark
Regional Hospital Viborg
Viborg, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.